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Abstract
Background—Identification of risk factors for lower extremity (LE) injury in sport and military/
first-responder occupations is required to inform injury prevention strategies.
Objective—To determine if poor movement quality is associated with LE injury in sport and 
military/first-responder occupations.
Material and methods—Five electronic databases were systematically searched. Studies 
selected included: original data; analytic design; movement quality outcome (qualitative rating of 
functional compensation, asymmetry, impairment or efficiency of movement control); LE injury 
sustained with sport or military/first-responder occupation. The PRISMA guidelines were 
followed. Two independent authors assessed the quality [Downs and Black (DB) criteria] and level 
of evidence (Oxford Centre of Evidence-Based Medicine model).
Results—Of 4361 potential studies, 17 were included. The majority were low quality cohort 
studies (level 4 evidence). Median DB score was 11/33 (range 3–15). Heterogeneity in 
methodology and injury definition precluded meta-analyses. The Functional Movement Screen 
was the most common outcome investigated (15/17 studies). Four studies considered 
interrelationships between risk factors, seven reported diagnostic accuracy and none tested an 
intervention program targeting individuals identified as high-risk. There is inconsistent evidence 
that poor movement quality is associated with increased risk of LE injury in sport and military/
first-responder occupations.
Conclusions—Future research should focus on high quality cohort studies to identify the most 
relevant movement quality outcomes for predicting injury risk followed by developing and 
evaluating pre-participation screening and LE injury prevention programs through high quality 
randomized controlled trials targeting individuals at greater risk of injury based upon screening 
tests with validated test properties.
Keywords
Athletic Injuries; Lower Extremity; Movement Screening; Occupational Injuries; Risk Factors
BACKGROUND
Due to the increasing prevalence and cost of treating chronic musculoskeletal (MSK) 
conditions such as hip, knee and ankle osteoarthritis (OA) there has been a call for scientific 
inquiry focused on shifting the approach taken to manage these conditions away from 
treatment and toward prevention.1 From an epidemiological perspective prevention of 
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chronic MSK conditions may include strategies aimed at reducing MSK injuries in 
susceptible populations (primary prevention) and/or strategies aimed at slowing down or 
halting the onset of the chronic MSK disorder after a MSK injury has occurred (secondary 
prevention). Susceptible populations for MSK injury include those that participate in sport 
and recreation, or have a service related occupation (e.g., military and first responders such 
as police officers, fire fighters and paramedics).23 For example epidemiological surveys have 
shown that the risk of injury is 1.5 to 2.0 times greater amongst individuals that participate 
in a variety of sporting and physical activities,2 and that MSK injury is the leading cause of 
disability in the military.4 In both of these at risk populations the most common MSK 
injuries are those that involve the lower extremities (LE).3
Van Mechelen5 proposed a 4-step model for injury prevention. This model involves 
establishing the extent of the specific injury burden of interest, followed by identifying 
injury risk factors and causal mechanisms through prospective analysis. The first two steps 
inform the development and introduction of preventative strategies (step four), which should 
then be evaluated to determine their impact on injury burden (step five). Finch et al6 
expanded upon this model emphasizing the importance of evaluating the effectiveness of 
preventative strategies in real-world implementation contexts and Meeuwisse et al7 
emphasized the importance of acknowledging that injury is a consequence of complex 
interactions of multiple risk factors and inciting events. Consequently, studies aimed at 
identifying risk factors for LE injuries and accompanying preventative strategies should 
engage end-users, utilize a prospective design and ensure an adequate sample size to 
facilitate biostatistical methods that consider the interrelationships between various risk 
factors.8 Further, to establish the value of injury risk screening on injury burden it is crucial 
that there is an accumulation of high quality evidence indicating that an intervention 
program targeting those at high risk of injury based on a screening program is more 
beneficial than a non-targeted intervention.9
Concomitant to injury prevention models is the development of approaches to identify ‘high-
risk’ individuals. Identification of these individuals enables prevention programs to be 
individually targeted, improving their effectiveness and public health impact (e.g., health 
care cost reduction). One method that is widely used to identify individuals at high-risk of 
injury are movement screening tests. The value of these tests is that they can be administered 
on-field or in clinical settings and are less costly than tests that require specialized 
equipment or highly trained personnel (e.g., laboratory tools such as 3D motion analysis). 
Additional advantages of movement screening tests are that they can be administered to a 
large number of individuals, are easily adapted to various sporting or occupation 
environments and provide almost immediate results. Further, as movement is modifiable, 
these tests provide information that can directly inform a prevention strategy and possibly 
assist in return to activity decisions.
Movement screening can involve the assessment of a single movement task or a composite 
battery of movement tasks. Further, participants can be assessed on their physical 
performance and/or the quality with which they move. Assessment of physical performance 
would consider a quantifiable outcome(s) of sport or occupational strength, power, balance, 
agility etc., often through multi-joint movements (e.g., Triple Single Leg Hop, Y Balance 
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Test).1011 Conversely, assessment of movement quality involves qualitative identification 
and rating of functional compensations, asymmetries, impairments or efficiency of 
movement control through transitional (e.g. squats, sit to stand, lunge) or dynamic 
movement (e.g. hopping, walking, running, landing, cutting) tasks. Both physical 
performance and movement quality assessments would ideally align with the sport or 
occupation specific context. Although there is consensus and several recent high-quality 
summaries of the clinimetric properties (e.g., validity, reliability and diagnostic accuracy) 
and evidence related to predicting injury risk and successful return to sport for physical 
performance outcomes,1011 the same cannot be said for movement quality outcomes.
As identification of risk factors and casual mechanisms are precursors to the development of 
effective prevention strategies, the lack of consensus related to movement quality risk factors 
for LE injury in sport and service occupations has likely hindered the process of developing 
and evaluating injury prevention strategies. The primary objective of this systematic review 
is to determine whether screening movement quality (a qualitative rating of functional 
compensation, asymmetry, impairment or efficiency of movement control either with 
individual movements tasks or a composite battery of movement tasks) can predict LE injury 
in sport and/or occupational (e.g., military, first responders) populations of all ages. A 
secondary objective is to summarize the clinimetric properties of the movement quality 
screening tests in the identified literature to inform clinicians and future research aimed at 
the development and use of movement quality screening.
METHODS
This review was registered in the PROSPERO database (CRD42015026958) and conducted 
according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) guidelines.12
Data Sources and Search
Relevant studies were identified by searching five online databases, selected based on their 
relevance to the research topics, from inception to January 2016. These databases included: 
Medline, EMBASE (Excerpta medical databases), CINAHL (Cumulative Index to Nursing 
and Allied Health Literature), Sport Discus, and SCOPUS. The combination of medical 
subject headings (MeSH) and text words that were used to execute each search was 
developed in consultation with a health sciences librarian scientist (LD). Appendix 1 
outlines the search terms used for population, injury type, screening type, screening quality, 
measurement as well as limits and exclusions, along with combinations of search terms that 
formed the final search strategy. The search strategy (specifically filters 3 and 4) from 
Kroman et al13 was heavily used as a source of search terms for screening quality and 
measurement concepts. Limits included: English language; human and MSK condition 
studies published in peer-reviewed journal. Articles were organized using the reference 
management software package, EndNote version 7.1 (Thomson Reuters, 2013). The number 
of references obtained from each search strategy for each database was recorded and a 
running total constructed. After accounting for duplication, the titles and corresponding 
abstracts of all returned records were independently reviewed by two of the authors blinded 
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to record author(s) and journal title using a Microsoft Excel workbook designed specifically 
for screening.14 Data were compiled and consensus (first between the two reviewers and if 
required by the lead author) regarding potentially relevant studies was reached on items in 
which there was disagreement. Prior to title and abstract review all authors independently 
screened a random sample of 120 titles and abstracts in which they were blinded to authors 
and journal title and reached strong agreement with the lead author (agreement ranging from 
81–97%, Kappa ranging from 0.13–0.49) using an Excel workbook designed specifically for 
this purpose.1415 Finally, two authors independently reviewed the full text of all potentially 
relevant studies to determine final study selection.
Study Selection
Studies were included if they investigated the prospective association between a movement 
quality outcome (defined as a qualitative rating of functional compensation, asymmetry, 
impairment or efficiency of movement control during either an individual movement task or 
battery of movement tasks) and MSK LE injury (defined as an injury involving the hip joint 
or distal). Additional inclusion criteria included: primary research with original data, 
analytic or intervention design, an outcome measure of LE injury sustained during sport or 
military/first-responder occupation participation and an objective exposure measure of one 
or more potential movement quality risk factor for LE injury. Studies were excluded if they 
were not written in English or involved animal models or cadavers. Further, conference 
proceedings or abstracts, editorials, commentaries, opinion-based papers review articles 
(systematic and narrative), case series, case studies, or studies in which screening did not 
take place prior to injury onset (e.g., cross-sectional) were excluded.
Data extraction and study rating process
Data extracted from each study included: study year; design; study location and population 
(e.g., sport, military/first-responder occupation, age, sample size); injury outcome (e.g., 
definition) and how it was ascertained; injury estimates (e.g., incidence proportion, 
incidence rate, prevalence); risk factors, and results (e.g., significant and non-significant) 
including measures of reliability, measures of risk [e.g., difference in means, correlations, 
odds ratio (OR), incidence rate ratios; IRR and risk ratio (RR)] and diagnostic accuracy 
(e.g., sensitivity, specificity, negative predictive value, positive predictive value, positive or 
negative likelihood ratios). Two authors independently assessed the quality and level of 
evidence of each study. Quality of evidence was evaluated based on criteria for internal 
validity (study design, quality of reporting, presence of selection and misclassification bias, 
potential confounding) and external validity (generalizability) using the Downs and Black 
(DB) quality assessment tool which assigns an individual score calculated out of 32 total 
points for each study (11 points for reporting, 3 points for external validity, 7 points for bias, 
6 points for confounding and 5 for power: Appendix 2)16. The level of evidence represented 
by each study was categorized based upon the Oxford Centre of Evidence Based Medicine 
(OCEBM) 2009 model (Appendix 3).17 As per study exclusion criteria, levels 1a, 2a, 3a 
(systematic reviews), 4 (case series) and 5 (opinion-based papers) were not included. 
Discrepancies in DB scoring or OCEBM categorization were resolved first by consensus 
between the two reviewers who rated the study and if required, by the lead author (JW).
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Data synthesis
Extracted data, quality and level of evidence were summarized for each study. The quantity, 
quality and level of evidence for the most commonly investigated movement quality risk 
factors for LE injury in sport military/first-responder occupation were collated.
RESULTS
Identification of studies
An overview of the study identification process is provided in Figure 1. The initial search 
yielded 8219 articles, 3858 duplicates were removed leaving 4361 potentially relevant 
articles. Following the removal of studies not meeting inclusion criteria based on abstract 
review (e.g., not human studies, ineligible study design, not sport or military/first-responder 
occupation, no LE injury, no movement quality risk factor, no association between a 
movement quality risk factor and LE injury) this was reduced to 119. Subsequent to full 
article evaluation by the two independent reviewers, 102 were excluded leaving 17 studies 
deemed appropriate for inclusion to the systematic review. Due to inconsistent methodology 
and injury definition, and heterogeneity of the risk factors examined, meta-analyses was 
precluded (see Table 1).
Study characteristics
Characteristics of the 17 included studies are summarized in Table 1. Sixteen of the 17 
studies were cohort studies, representing four countries (13 from the United States,18–30 1 
each from Canada31, Iran32 and Japan33) published between 2007 and 2015. 
Thirteen181922–2528–34 of the studies investigated the value of movement quality screening 
for athletes (including three182425 involving professional athletes and four22232930 involving 
National Collegiate Athletic Association athletes22232930; 2128 total participants; 1159 
males and 817 females), two2027 in the military (total male participants 3350) and two2126 in 
first responder trainees (total participants 1153; unable to distinguish by sex). 
Fourteen18–2024–34 of the studies are believed to have included male participants, while 
seven19222628293234 of the studies included female participants. Five2123–2530 of the studies 
did not specify participant sex however based on the sport or military group investigated in 
three242530 of these it is likely the participants were male. The age range of the athletes was 
11–25 years, military members 18–57 years and first responder trainees 11–22 years. One of 
the studies involving first responder trainees21 and three182425 with athletes did not report 
age range. Amongst the 17 studies, three202627 had a sample size greater than 500, 
five2023252930 had at least 50 injury cases (range 7–916 with three not reporting the number 
of injured participants) and four20272933 utilized a multivariable statistical approach to 
identify if movement quality outcomes could identify injury risk. Five2224252831 of the 17 
studies included a metric of diagnostic accuracy and no studies were identified that assessed 
the value of screening for movement quality on reducing the burden of LE injury.
Clinimetric Properties
Fifteen18–2729–33 of the 17 studies (88%) employed the Functional Movement Screen (FMS) 
to assess movement quality, while two2834 used the Lower Extremity Scoring System 
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(LESS). Of those using the FMS only three222333 investigated the reliability of their 
measurement system while one34 of the investigations employing the LESS embedded an 
assessment of reliability into the study design. The most common reliability statistic 
estimated was an intraclass correlation coefficient with two2933 of the 17 studies including 
95% confidence intervals (CI). One33 study reported estimates of measurement precision.
Injury estimates
Descriptions of injury estimates (incidence proportion, incidence rate, prevalence), effect 
estimates (IRR, RR, OR) and significant and non-significant movement quality outcomes are 
presented in Table 1.
Quality and level of evidence
The highest level of evidence demonstrated by all reviewed studies was level 2b (cohort 
study) with the majority (13/17) of studies classified as level 4 which corresponds to low 
quality cohort study (n< 500, injury sample < 50, lack of multivariable analyses).
The median methodological quality for all 21 studies, based on the DB criteria, was 11/33 
(range 3–15) with only 9/17 scoring greater than 10. The aim of the DB criteria is to assess 
scientific study methodological quality (inclusive of randomized and non-randomized 
intervention as well as observational studies). As all of the included studies were 
observational in nature, 7 items (4, 8, 14, 19, 23, 24, and 27; totaling 10 points) on the DB 
checklist were not applicable. Areas in which the included studies were consistently limited 
included: incomplete description of how the sample was representative of the population of 
interest (e.g., insufficient description of participant characteristics such as sex, history of 
previous injury, training exposure); limited description of the characteristics of those lost to 
follow-up; insufficient reporting of how participants were lost to follow-up and differing 
length of follow-up were accounted for in statistical analyses; inadequate sample size; and 
lack of adjustment for potential modification and confounding by factors, such as exposure 
and previous injury. Of further note is the fact that two of the studies reported significant 
findings even though the 95%CI of the statistical estimate included a null value and that 
11/17 studies were published in non-indexed journals or in journals with an impact factor 
less than 2.
Synthesis of results
The quantity, quality and level of evidence for the most commonly investigated movement 
quality outcomes are summarized in Table 3. The most common risk factors investigated 
included age, FMS total score, FMS total score ≤14, FMS total score ≤12, FMS hurdle step, 
FMS in-line lunge, FMS deep squat, LESS total score and LESS total score ≥5. Based on 
this synthesis there is inconsistent evidence that poor movement quality is associated with 
increased risk of LE injury in sport and military/first-responder occupation.
DISCUSSION
To our knowledge, this is the first systematic review examining movement quality risk 
factors for LE injury in sport and military/first responder occupations that incorporates both 
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a formal evaluation of study quality and level of evidence. Overall there is inconsistent level 
4 evidence that poor movement quality is a risk factor for LE injury in sport and military/
first-responder occupation populations. Accordingly, as the identification of risk factors is 
the first step in the injury prevention, it remains unknown if movement quality screening has 
a role in reducing the burden of LE injury in these populations.
It is important to highlight that the findings of this review are based upon a synthesis and 
evaluation of existing literature, and as such they are limited by the inadequacies of studies 
included. Overall there was a lack of consistent high quality evidence to support nominating 
any particular movement quality outcome as a risk factor due to inadequate reporting of 
concepts essential to establishing internal and external validity. The biggest threats to 
internal validity were related to the possibility of selection bias, and the reporting of, and 
adjustment for, potential confounding by factors such as sex, injury history and training 
exposure. Specifically, due to the lack of participant characteristic reporting it was often 
difficult to determine if the individuals selected for a study differed systematically from 
those in the source population. Equally important was the consistent omission of the 
characteristics of those lost to follow-up, which made it impossible to determine if 
participants lost to follow-up were systematically different from those retained in a study. 
The inability to determine selection bias not only questions the internal validity of several 
included studies, it impacts the degree to which the findings of these studies can be 
generalized to the larger population from which the samples were drawn (external validity).
As indicated earlier, it is highly unlikely that a LE injury is a result of a single risk factor or 
aberrant movement pattern, but rather the consequence of complex interactions between 
multiple risk factors and inciting events.7 Multivariable biostatistical techniques can explore 
these complex interactions given an adequate sample size. Bahr and Holme8 estimated that 
50 injury cases are needed to detect a moderate to strong association between a risk factor 
and injury. Of the 17 studies included in this review only four20272933 employed 
multivariable biostatistical techniques, of which only two2029 had 50 or more injury cases 
(with one27 not reporting the number of injury cases) and were able to assess the influence 
of additional covariates (e.g., body mass index, smoking status, muscular and cardiovascular 
fitness, battalion, previous injury history, sex, age and sport). As sex, previous injury, and 
exposure to training are known to influence the incidence of MSK LE injury the lack of 
reporting and assessment of the impact of these factors on the association between a pre-
season movement quality deficit and injury incidence with adequate sample size and 
biostatistical techniques brings into question the value of only assessing movement quality 
to establish injury risk.
It is important to consider that the true value of being able to identify risk factors for future 
injury is dependent upon it actually leading to strategies that result in injury reduction in real 
world contexts. This empirical validation requires an accumulation of high quality evidence 
indicating that an intervention program targeting those at high risk of injury based on a 
screening test is more beneficial than a non-targeted intervention.9 However before such a 
hypothesis can be tested there needs to be an accumulation of high quality evidence 
demonstrating a strong relationship between the risk factor, which was assessed with a valid 
and reliable screening test employing a specific cut-off value, and injury. Further, the 
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predictive ability of the specific screening test cut-off value must be validated in multiple 
populations.9
To date, movement quality tests lack the foundation of rigorous development and validation 
(e.g. psychometrics) common in other fields35 and there is a lack of high quality evidence 
demonstrating a strong relationship between any single movement quality outcome and 
injury. As movement quality tests were not specifically developed as diagnostic tools, but 
rather to identify deficits that inform clinical interventions from a mechanistic perspective, 
this is perhaps not surprising.936 Although several cut-off points for high LE injury risk have 
been proposed (e.g., FMS total score ≤ 14,24 FMS total score ≤12,30 and LESS total score 
≥528), none appear to have sufficient diagnostic accuracy to be useful in real world contexts. 
For example the sensitivity and specificity of a FMS total score ≤14 has been shown be 
between 0.54–0.83 and 0.61–0.91 respectively.22242537 This suggests that almost half of 
individuals that go on to suffer a injury may not have a FMS total score ≤14 and over half of 
those that do not go on to suffer an injury may not have a FMS total score ≤14.
The ability to establish a link between poor movement quality and injury risk hold great 
potential for identifying modifiable causal mechanisms for injury, which can be addressed 
with a targeted intervention. For example the LESS aims to identify movement quality errors 
during jump-landing28 such as decreased hip flexion and knee valgus that have been 
associated with anterior cruciate ligament injury. In doing so provides a starting point for 
targeted interventions aimed at improving jump-landing mechanics and reducing an 
individual’s future ACL injury risk. However, the link between other movement quality 
outcomes that have an association with LE injury, such as reduced shoulder mobility19 or 
other FMS components, is not as intuitive. Without a theoretical basis linking the ‘non-
optimal movement’ to the injury, it would be difficult to know how to use the finding of an 
“abnormal” movement to guide an intervention aimed at reducing injury risk. This is a 
limitation of some movement quality outcomes that will have to be addressed prior to 
widespread application.
A final consideration is that this review was unable to identify any investigation that had 
assessed the value of screening for movement quality for reducing the burden of LE injury 
through targeted interventions in sport or military/first-responder occupation populations. 
With that said there are several examples of attempts to do this in the field of sport injury 
prevention using physical performance outcomes that can provide valuable guidance3839 
Specifically, these studies highlight the importance of developing an implementation 
strategy in conjunction with the intervention and then tracking and accounting for adherence 
to the prevention programs in the analysis.
Limitations
Meta-analyses were not possible due to the fact that the assumptions for meta-analyses were 
not satisfied by the included studies. In particular, there was considerable inconsistency in 
methodology (e.g., reporting and controlling for confounding) and heterogeneity of injury 
definition. For example, the injury definition covered the span of ‘a MSK injury resulting 
from organized intercollegiate sport practice or competition that required medical attention 
or advice from a certified athletic trainer, athletic training student or physician’22 to ‘a MSK 
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injury that occurred during participation in track and field practice or competition that 
prevented participation for 4 weeks’33. This inconsistency in injury definition led to injury 
estimates ranging from 0.8 % to 85% of participants across the included studies. Further, 
despite a comprehensive search strategy and rigorous approach to study selection, it is 
important to acknowledge the possibility of omitting a relevant study and inclusion of only 
English language articles as additional potential limitations. Finally, as the findings of this 
review are based upon a synthesis and evaluation of existing literature it is important to point 
out that the current evidence base of studies that have assessed the prospective relationship 
between poor movement quality and LE injury may not have considered all possible 
movement quality screening tests (e.g., Nine Battery Test,40 Performance Matrix,41 Single 
Leg Squat,42–44 Tuck Jump Assessment and Star Excursion Balance Test45).
Recommendations
Both cohort and intervention study designs can play an important role in identifying 
potential risk factors and reducing the burden of LE injury in sport and military/first-
responder occupations.89 While cohort studies are critical for establishing temporality 
between a risk factor and subsequent injury, randomized controlled trials (RCTs) provide the 
strongest evidence for the causal nature of a risk factor and the effectiveness of modifying 
that factor on injury burden. Based upon the studies reviewed it is recommended that future 
research focus on high quality cohort studies aimed at identifying the most relevant 
movement quality outcomes for predicting injury followed by establishing the diagnostic 
accuracy of the movement quality screening tests used to assess these risk factors in relevant 
populations. Given the challenges and high cost of undertaking high quality cohort studies, 
an alternative approach may be to simultaneously develop and evaluate pre-participation 
screening and LE injury prevention programs through high quality RCT’s targeting athletes 
or workers at greater risk of injury based upon previous injury. Further recommendations 
include; ensuring consistency in injury definition amongst studies attempting to determine 
the relationship between a movement quality outcome and subsequent injury that aligns with 
international consensus46 and the development of movement quality screening tools 
according to psychometric principles.35 Implementation of these recommendations will 
assist in the advancement of injury prediction and prevention.
CONCLUSIONS
Based on the findings of this systematic review it is recommended future research focus on 
high quality cohort studies to identify the most relevant movement quality outcomes for 
predicting injury. This should be followed by development and evaluation of pre-
participation screening and LE injury prevention programs through high quality randomized 
controlled trials targeting athletes or workers at greater risk of injury based upon 
psychometrically sound movement screening tests.
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APPENDIX 1: SEARCH TERMS, STRATEGIES AND RESULTS
SEARCH TERMS AND STRATEGIES
1. Search Concepts
• athletic and first responders and military
• injuries
• lower extremity
• movement
• measuring quality
• lower extremity movement quality tests (meet criteria of above 3 concepts)
• clinimetric properties
• limits and exclusions
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2. Search terms and Strategies
a. Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present
1. Athletic Injuries/
2. exp Sports/
3. Athletes/
4. Military Personnel/
5. exp Emergency Responders/
6. (sport or sports or athlet* or runners or (run* adj2 (marathon* or competitive* or 
casual* or recreation*)) or joggers or police* or officer* or firefighter* or firem* 
or fire personnel or military or army or navy or air force or airforce or soldier* or 
armed forces or armed service* or active duty* or veteran* or paramedic or first 
responder* or (emergency adj2 responder*) or ambulance or emergency medical 
technician*).mp.
7. (active adj3 (individual* or population* or participant* or male* or female* or 
men or women or persons or students or adult* or patients or adolescent*)).mp.
8. or/1–7
9. exp hip injuries/or exp leg injuries/or hip dislocation/or knee dislocation/or 
patellar dislocation/
10. femoracetabular impingement/or patellofemoral pain syndrome/
11. ((injur* or pain* or tear or tears or sprain* or strain* or dislocation* or 
impingement* or instability) adj6 (risk or risks or predict* or associat* or 
correlat* or screen* or prevent* or sport* or athletic or running)).mp.
12. ((injur* or pain* or tear or tears or sprain* or strain* or dislocation* or 
impingement* or instability) adj8 (lower extremit* or lower limb* or hip or hips 
or thigh or thighs or leg or legs or knee or knees or ankle* or foot or foots or toe 
or toes or ACL or PCL or ((anterior or posterior) adj cruciate adj2 ligament*) or 
femoracetabular or femur or (menisc* adj3 (tibia* or lateral)) or 
patellofemoral)).mp.
13. “Sprains and Strains”/
14. Joint Instability/
15. Pain/
16. Athletic Injuries/
17. Dislocations/
18. “Wounds and Injuries”/
19. or/9–18
Whittaker et al. Page 14
Br J Sports Med. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
20. exp hip injuries/or exp leg injuries/or hip dislocation/or knee dislocation/or 
patellar dislocation/
21. (lower extremit* or lower limb* or hip or hips or thigh or thighs or leg or legs or 
knee or knees or ankle* or foot or foots or toe or toes or ACL or PCL or 
((anterior or posterior) adj cruciate adj2 ligament*) or femoracetabular or femur 
or (menisc* adj3 (tibia* or lateral)) or patellofemoral).mp.
22. (run or running or jog* or squat* or minisquat* or balance or lunge or lunges or 
hop or jump or jumping or walk or walking or step-up or hurdle or gait).mp.
23. 20 or 21 or 22
24. motor activity/
25. (exercis* or (physical adj (activit* or perform* or function*))).mp.
26. (function* adj (activ* or perform*)).mp.
27. (motor or movement or motion or dynamic or moving).mp.
28. (run or running or jog* or squat* or minisquat* or balance or lunge or lunges or 
hop or jump or jumping or walk or walking or step-up or hurdle or gait).mp.
29. or/24–27
30. “Task Performance and Analysis”/
31. (functional test* or grade or grading or rating or rated or score or scoring or rank 
or ranked or ranking).mp.
32. (control adj6 (assess* or test* or measur*)).mp.
33. (movement adj2 (screen* or assess* or quality or performance or observation or 
observe* or test*)).mp.
34. ((performance or objective or observation* or quality) adj5 (measur* or test* or 
instrument* or method or methods or index or indices or assess* or 
screen*)).mp.
35. ((deficit* or varus or valgus or asymmetr* or compensatory movement) and 
(measur* or test* or instrument* or method or methods or index or indices or 
assess* or screen*)).mp.
36. or 30–35
37. (((Lunge or Squat or Hop or jump or Reach or Cutting or Step-up or Balance or 
Push-up or Lift or Rotation or walk*) adj3 (test* or task* or assessment)) or gait 
analys* or gait evaluation*).mp.
38. (deep squat* or one leg squat* or mini-squat* or mini squat* or “in line lunge*” 
or inline lunge* or double leg drop vertical jump* or “hop and hold*” or Hurdle 
step* or single leg pickup or single leg pick-up or single leg land or single leg 
balance or leg raise or tuck jump or vertical jump or drop jump).mp.
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39. (Functional movement screen* or PPM-16 or ((nine-test or movement or 
performance or function) adj3 screening battery) or landing error scoring 
system* or balance error scoring system*).mp.
40. or/37–39
41. (23 and 29 and 36 and 40)
42. predictive value.mp.
43. (predict* or associat* or correlat*).ti.
44. ((predict* or correlat* or associat*) adj10 (injur* or pain* or tear or tears or 
sprain* or strain* or dislocation* or impingement* or instability)).mp.
45. (receiver operator curve* or ROC or likelihood ratio* or specificity or ((positive* 
or negative* or high* or low) adj4 correlat*)).mp.
46. validation studies/
47. Comparative Study/
48. “Outcome Assessment (Health Care)”/
49. observer variation/
50. Health Status Indicators/
51. exp “reproducibility of results”/
52. discriminant analysis/
53. (outcome assessment or outcome measure or observer variation or 
instrumentation or psychometr* or clinimetr* or clinometr* or reproducib* or 
reliab* or unreliab* or valid* or coefficient or homogeneity or homogeneous or 
internal consistency).mp.
54. ((cronbach* adj2 alpha*) or (item adj5 (correlation* or selection* or reduction*)) 
or agreement or precision or imprecision or precise value* or test-retest or (test 
adj3 retest) or stability).mp.
55. (interrater or inter-rater or intrarater or intra-rater or intertester or inter-tester or 
intratester or intra-tester or interobserver or inter-observer or intraobserver or 
intraobserver or intertechnician or inter-technician or intratechnician or intra-
technician or interexaminer or inter-examiner or intraexaminer or intra-examiner 
or interassay or inter-assay or intraassay or intra-assay or interindividual or inter-
individual or intraindividual or intra-individual or interparticipant or 
interparticipant or intraparticipant or intra-participant).mp.
56. (kappa* or repeatab* or ((replicab* or repeated) adj6 (measure or measures or 
findings or result or results or test or tests)) or generaliza* or generalisa* or 
concordance or (intraclass and correlation*) or discriminative or known group or 
factor analysis or factor analyses or dimension* or subscale* or (multitrait adj6 
scaling adj6 analys*) or item discriminant or interscale correlation* or error or 
errors or individual variability or (variability adj8 (analysis or values)) or 
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(uncertainty adj6 (measurement or measuring)) or standard error of measurement 
or sensitiv* or responsive* or ((minimal or minimally or clinical or clinically or 
mall*) adj6 (important or significant or detectable or real) adj6 (change or 
difference)) or meaningful change or ceiling effect or floor effect or Item 
response model or IRT or Rasch or Differential item functioning or DIF or 
computer adaptive testing or item bank or cross-cultural equivalence).mp.
57. or/42–56
58. 8 and 19 and 41 and 57
59. limit 58 to animals
60. limit 59 to humans
61. (mice or mouse or rat or rats or animal model* or bovine or rodent*).ti.
62. 58 not ((59 not 60) or 61)
63. (arthroplast* or arthroscop* or TKA or THA or surgery or surgical).ti.
64. ((after or undergoing) adj5 reconstruction).ti.
65. (paraplegi* or brain injur* or stroke or post-stroke or concussion or 
polyneuropath* or fibromyalgia or multiple sclerosis or arteriosclerosis or cancer 
or neoplasm* or malignanc* or degenerative).ti.
66. “return to sport”.ti.
67. (claudication or epidural or platelet-rich plasma or cadaver or spinal cord or 
spinal chord or vibration or arterial disease or caffeine or pregnan* or breast or 
breasts or steroid*).ti.
68. 62 not (or/63–67)
69. limit 68 to “review articles”
70. 68 not 69
71. case reports/
72. case report*.jw.
73. ((case not (case control or case cohort or case crossover)) adj4 (series or study or 
report*)).ti.
74. 70 not (or/71–73)
75. limit 74 to english language
b. Embase 1974 to 2015 December 31
1. sport injury/or battle injury/
2. exp sport/
3. athlete/
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4. soldier/
5. rescue personnel/
6. (sport or sports or athlet* or runners or (run* adj2 (marathon* or competitive* or 
casual* or recreation*)) or joggers or police* or officer* or firefighter* or firem* 
or fire personnel or military or army or navy or air force or airforce or soldier* or 
armed forces or armed service* or active duty* or veteran* or paramedic or first 
responder* or (emergency adj2 responder*) or ambulance or emergency medical 
technician*).mp.
7. (active adj3 (individual* or population* or participant* or male* or female* or 
men or women or persons or students or adult* or patients or adolescent*)).mp.
8. or/1–7
9. sport injury/or battle injury/
10. exp leg pain/or exp leg injury/or femoroacetabular impingement/or ankle sprain/
11. injury/or injury prediction/or limb injury/or musculoskeletal injury/or soft tissue 
injury/or tissue injury/or sprain/or joint injury/or dislocation/or joint fracture/or 
joint instability/
12. ((injur* or pain* or tear or tears or sprain* or strain* or dislocation* or 
impingement* or instability) adj6 (risk or risks or predict* or associat* or 
correlat* or screen* or prevent* or sport* or athletic or running)).mp.
13. ((injur* or pain* or tear or tears or sprain* or strain* or dislocation* or 
impingement* or instability) adj8 (lower extremit* or lower limb* or hip or hips 
or thigh or thighs or leg or legs or knee or knees or ankle* or foot or foots or toe 
or toes or ACL or PCL or ((anterior or posterior) adj cruciate adj2 ligament*) or 
femoracetabular or femur or (menisc* adj3 (tibia* or lateral)) or 
patellofemoral)).mp.
14. or 9–13
15. exp leg pain/or exp leg injury/or femoroacetabular impingement/or ankle sprain/
16. hip/or exp leg/or exp “bones of the leg and foot”/or quadratus femoris muscle/or 
quadriceps femoris muscle/or sartorius muscle/or soleus muscle/or tibialis 
anterior muscle/or tibialis posterior muscle/or vastus lateralis muscle/or vastus 
medialis muscle/or ligament/or ankle lateral ligament/or exp knee ligament/or 
“ligament of head of femur”/or patella ligament/
17. (lower extremit* or lower limb* or hip or hips or thigh or thighs or leg or legs or 
knee or knees or ankle* or foot or foots or toe or toes or ACL or PCL or 
((anterior or posterior) adj cruciate adj2 ligament*) or femoracetabular or femur 
or (menisc* adj3 (tibia* or lateral)) or patellofemoral).mp.
18. (run or running or jog* or squat* or minisquat* or balance or lunge or lunges or 
hop or jump or jumping or walk or walking or step-up or hurdle or gait).mp.
19. or/15–18
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20. motor activity/or physical activity/or physical performance/or “physical activity, 
capacity and performance”/or motor performance/
21. (exercis* or (physical adj (activit* or perform* or function*))).mp.
22. (function* adj (activ* or perform*)).mp.
23. (motor or movement or motion or dynamic or moving).mp.
24. (run or running or jog* or squat* or minisquat* or balance or lunge or lunges or 
hop or jump or jumping or walk or walking or step-up or hurdle or gait).mp.
25. or/20–24
26. (functional test* or grade or grading or rating or rated or score or scoring or rank 
or ranked or ranking).mp.
27. (control adj6 (assess* or test* or measur*)).mp.
28. (movement adj2 (screen* or assess* or quality or performance or observation or 
observe* or test*)).mp.
29. ((performance or objective or observation* or quality) adj5 (measur* or test* or 
instrument* or method or methods or index or indices or assess* or 
screen*)).mp.
30. ((deficit* or varus or valgus or asymmetr* or compensatory movement) and 
(measur* or test* or instrument* or method or methods or index or indices or 
assess* or screen*)).mp.
31. or/26–30
32. (((Lunge or Squat or Hop or jump or Reach or Cutting or Step-up or Balance or 
Push-up or Lift or Rotation or walk*) adj3 (test* or task* or assessment)) or gait 
analys* or gait evaluation*).mp.
33. (deep squat* or one leg squat* or mini-squat* or mini squat* or “in line lunge*” 
or inline lunge* or double leg drop vertical jump* or “hop and hold*” or Hurdle 
step* or single leg pickup or single leg pick-up or single leg land or single leg 
balance or leg raise or tuck jump or vertical jump or drop jump).mp.
34. (Functional movement screen* or PPM-16 or ((nine-test or movement or 
performance or function) adj3 screening battery) or landing error scoring 
system* or balance error scoring system*).mp.
35. or/32–34
36. (19 and 25 and 31) or 35
37. predictive value.mp.
38. (predict* or associat* or correlat*).ti.
39. ((predict* or correlat* or associat*) adj10 injur*).mp.
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40. (receiver operator curve* or ROC or likelihood ratio* or specificity or ((positive* 
or negative* or high* or low) adj4 correlat*)).mp.
41. validation study/
42. comparative study/
43. outcome assessment/
44. observer variation/
45. health status indicator/
46. exp measurement precision/
47. statistical parameters/or exp reliability/or exp validity/
48. discriminant analysis/
49. (outcome assessment or outcome measure or observer variation or 
instrumentation or psychometr* or clinimetr* or clinometr* or reproducib* or 
reliab* or unreliab* or valid* or coefficient or homogeneity or homogeneous or 
internal consistency).mp.
50. ((cronbach* adj2 alpha*) or (item adj5 (correlation* or selection* or reduction*)) 
or agreement or precision or imprecision or precise value* or test-retest or (test 
adj3 retest) or stability).mp.
51. (interrater or inter-rater or intrarater or intra-rater or intertester or inter-tester or 
intratester or intra-tester or interobserver or inter-observer or intraobserver or 
intraobserver or intertechnician or inter-technician or intratechnician or intra-
technician or interexaminer or inter-examiner or intraexaminer or intra-examiner 
or interassay or inter-assay or intraassay or intra-assay or interindividual or inter-
individual or intraindividual or intra-individual or interparticipant or 
interparticipant or intraparticipant or intra-participant).mp.
52. (kappa* or repeatab* or ((replicab* or repeated) adj6 (measure or measures or 
findings or result or results or test or tests)) or generaliza* or generalisa* or 
concordance or (intraclass and correlation*) or discriminative or known group or 
factor analysis or factor analyses or dimension* or subscale* or (multitrait adj6 
scaling adj6 analys*) or item discriminant or interscale correlation* or error or 
errors or individual variability or (variability adj8 (analysis or values)) or 
(uncertainty adj6 (measurement or measuring)) or standard error of measurement 
or sensitiv* or responsive* or ((minimal or minimally or clinical or clinically or 
mall*) adj6 (important or significant or detectable or real) adj6 (change or 
difference)) or meaningful change or ceiling effect or floor effect or Item 
response model or IRT or Rasch or Differential item functioning or DIF or 
computer adaptive testing or item bank or cross-cultural equivalence).mp.
53. or/37–52
54. 8 and 14 and 36 and 53
55. limit 54 to animals
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56. (mice or mouse or rat or rats or animal model* or bovine or rodent*).ti.
57. 54 not (55 or 56)
58. (arthroplast* or arthroscop* or TKA or THA or surgery or surgical).ti.
59. ((after or undergoing) adj5 reconstruction).ti.
60. (paraplegi* or brain injur* or stroke or post-stroke or concussion or 
polyneuropath* or fibromyalgia or multiple sclerosis or arteriosclerosis or cancer 
or neoplasm* or malignanc* or degenerative).ti.
61. “return to sport”.ti.
62. (claudication or epidural or platelet-rich plasma or cadaver or spinal cord or 
spinal chord or vibration or arterial disease or caffeine or pregnan* or breast or 
breasts or steroid*).ti.
63. 57 not (or/58–62)
64. limit 63 to (conference abstract or “conference review” or “review”)
65. 63 not 64
66. case report/
67. case study/
68. case report*.jx.
69. ((case not (case control or case cohort or case crossover)) adj4 (series or study or 
report*)).ti.
70. 65 not (66 or 67 or 68)
71. limit 70 to english language
c. CINAHL Plus with Full Text—Search mode: Boolean/Phrase
S1 ( (MH “Athletic Injuries+”) OR (MH “Sports+”) OR (MH “Military Personnel
+”) ) OR ( sport or sports or athlet* or runners or (run* n2 (marathon* or 
competitive* or casual* or recreation*)) or joggers or police* or officer* or 
firefighter* or firem* or “fire personnel” or military or army or navy or “air 
force” or airforce or soldier* or “armed forces” or “armed service*” or “active 
duty*” or veteran* or paramedic or “first responder*” or (emergency n2 
responder*) or ambulance or “emergency medical technician*” ) OR ( active n3 
(individual* or population* or participant* or male* or female* or men or 
women or persons or students or adult* or patients or adolescent*) )
S2 ( (MH “Leg Injuries+”) OR (MH “Knee Pain+”) OR (MH “Femoracetabular 
Impingement”) OR (MH “Wounds and Injuries”) OR (MH “Fractures”) OR 
(MH “Sprains and Strains”) OR (MH “Dislocations”) OR (MH “Athletic 
Injuries+”) OR (MH “Tendon Injuries”) OR (MH “Pain”) OR (MH “Joint 
Instability”) ) OR ( (injur* or pain* or tear or tears or sprain* or strain* or 
dislocation* or impingement* or instability) n6 (risk or risks or predict* or 
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associat* or correlat* or screen* or prevent* or sport* or athletic or running) ) 
OR ( (injur* or pain* or tear or tears or sprain* or strain* or dislocation* or 
impingement* or instability) n8 (“lower extremit*” or “lower limb*” or hip or 
hips or thigh or thighs or leg or legs or knee or knees or ankle* or foot or foots 
or toe or toes or ACL or PCL or (cruciate n2 ligament*) or femoracetabular or 
femur or tibia* or patellofemoral or patella*) )
S3 ( (MH “Leg Injuries+”) OR (MH “Knee Pain+”) OR (MH “Femoracetabular 
Impingement”) ) OR ( “lower extremit*” or “lower limb*” or hip or hips or 
thigh or thighs or leg or legs or knee or knees or ankle* or foot or foots or toe or 
toes or ACL or PCL or (cruciate n2 ligament*) or femoracetabular or femur or 
tibia* or patellofemoral or patella* ) OR ( run or running or jog* or squat* or 
minisquat* or balance or lunge or lunges or hop or jump or jumping or walk or 
walking or step-up or hurdle or gait )
S4 ( motor or movement or motion or dynamic or moving ) OR ( exercis* or 
(physical n1 (activit* or perform* or function*)) ) OR ( (function* n1 (activ* or 
perform*)) ) OR ( run or running or jog* or squat* or minisquat* or balance or 
lunge or lunges or hop or jump or jumping or walk or walking or step-up or 
hurdle or gait )
S5 (MH “Task Performance and Analysis”) OR ( “functional test*” or grade or 
grading or rating or rated or score or scoring or rank or ranked or ranking ) OR 
( movement n2 (screen* or assess* or quality or performance or observation or 
observe* or test*) ) OR ( (performance or objective or observation* or quality or 
control) n5 (measur* or test* or instrument* or method or methods or index or 
indices or assess* or screen*) ) OR (( deficit* or varus or valgus or asymmetr* 
or “compensatory movement”) and (measur* or test* or instrument* or method 
or methods or index or indices or assess* or screen* ))
S6 ( (Lunge or Squat or Hop or jump or Reach or Cutting or Step-up or Balance or 
Push-up or Lift or Rotation or walk*) n3 (test* or task* or assessment) ) OR 
( “gait analys*” or “gait evaluation*” or “deep squat*” or “one leg squat*” or 
mini-squat* or “mini squat*” or “in line lunge*” or “inline lunge*” or “double 
leg drop” or “hop and hold*” or “Hurdle step*” or “single leg pickup” or “single 
leg pick-up” or “single leg land” or “single leg balance” or “leg raise” or “tuck 
jump” or “vertical jump” or “drop jump” ) OR ( “functional movement screen*” 
or “landing error scoring system*” or “balance error scoring system*” or 
ppm-16 ) OR ( (nine-test or movement or performance or function) n3 
“screening battery” )
S7 (S3 AND S4 AND S5) OR S6
S8 TI (predict* or associat* or correlat*)
S9 (MH “Discriminant Analysis”) or (MH “Health Status Indicators”) or (MH 
“Comparative Studies”)
S10 ( “predictive value” or “receiver operator curve*” or ROC or “likelihood ratio*” 
or specificity ) OR ( (predict* or correlat* or associat*) n10 (injur* or pain* or 
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tear or tears or sprain* or strain* or dislocation* or impingement* or 
instability) ) OR ( (positive* or negative* or high* or low) n4 correlat*) ) OR 
( “outcome assessment” or “outcome measure*” or “observer variation*” or 
instrumentation or psychometr* or clinimetr* or clinometr* or reproducib* or 
reliab* or unreliab* or valid* or coefficient or homogeneity or homogeneous or 
“internal consistency”)
S11 ( (item n5 (correlation* or selection* or reduction*) ) OR ( “cronbach* alpha” or 
agreement or precision or imprecision or “precise value*” or test-retest or (test 
n3 retest) or stability ) OR ( interrater or inter-rater or intrarater or intra-rater or 
intertester or inter-tester or intratester or intra-tester or interobserver or inter-
observer or intraobserver or intraobserver or intertechnician or inter-technician 
or intratechnician or intra-technician or interexaminer or inter-examiner or 
intraexaminer or intra-examiner or interassay or inter-assay or intraassay or 
intra-assay or interindividual or inter-individual or intraindividual or intra-
individual or interparticipant or interparticipant or intraparticipant or intra-
participant )
S12 ( (replicab* or repeated) n6 (measure or measures or findings or result or results 
or test or tests) ) OR ( kappa* or repeatab* or generaliza* or generalisa* or 
concordance or (intraclass and correlation*) or discriminative or “known group” 
or “factor analysis” or “factor analyses” or dimension* or subscale* ) OR 
(multitrait n6 scaling n6 analys*) OR ( “item discriminant” or “interscale 
correlation*” or error or errors or “individual variability” or “standard error of 
measurement” or sensitiv* or responsive* ) OR ( variability n8 (analysis or 
values) ) OR ( uncertainty n6 (measurement or measuring) ) OR ( (minimal or 
minimally or clinical or clinically or mall*) n6 (important or significant or 
detectable or real) n6 (change or difference) ) OR ( “meaningful change” or 
“ceiling effect” or “floor effect” or “item response model” or IRT or Rasch or 
“Differential item functioning” or DIF or “computer adaptive testing” or “item 
bank” or “crosscultural equivalence” )
S13 S8 OR S9 OR S10 OR S11 OR S12
S14 S1 AND S2 AND S7 AND S13
S15 TI ( ice or mouse or rat or rats or animal model* or bovine or rodent* ) OR TI 
( arthroplast* or arthroscop* or TKA or THA or surgery or surgical or 
paraplegi* or brain injur* or stroke or post-stroke or concussion or 
polyneuropath* or fibromyalgia or multiple sclerosis or arteriosclerosis or 
cancer or neoplasm* or malignanc* or degenerative or “return to sport” or 
claudication or epidural or platelet-rich plasma or cadaver or spinal cord or 
spinal chord or vibration or arterial disease or caffeine or pregnan* or breast or 
breasts or steroid* ) OR TI ( (after or undergoing) n5 reconstruction )
S16 PT review
S17 (MH “Case Studies”)
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S18 TI ((case NOT (case control or case cohort or case crossover)) n4 (series or 
study or report*))
S19 SO case report*
S20 S14 NOT ( (S15 OR S16 OR S17 OR S18 OR S19) )
S21 S20 Limiters - Language: English
d. SPORTDiscus—Search mode: Boolean/Phrase
S1 AB ( ( athlet* or players or sport or sports or rugby or netball* or basketball* or 
hockey or volleyball or skiers or snowboard* or soccer or football* or lacrosse 
or rowers or gymnasts or “figure skaters” or dancers or tennis or badminton ) 
OR ( runners or (run* n2 (marathon* or competitive* or casual* or recreation*)) 
or joggers or police* or officer* or firefighter* or firem* or “fire personnel” or 
military or army or navy or “air force” or airforce or soldier* or “armed forces” 
or “armed service*” or “active duty*” or veteran* or paramedic or “first 
responder*” or (emergency n2 responder*) or ambulance or “emergency medical 
technician*” ) OR ( active n3 (individual* or population* or participant* or 
male* or female* or men or women or persons or students or adult* or patients 
or adolescent*) ) ) OR KW ( ( athletes or players or sport or sports or rugby or 
netball* or basketball* or hockey or volleyball or skiers or snowboard* or soccer 
or football* or lacrosse or rowers or gymnasts or “figure skaters” or dancers or 
tennis or badminton ) OR ( runners or (run* n2 (marathon* or competitive* or 
casual* or recreation*)) or joggers or police* or officer* or firefighter* or firem* 
or “fire personnel” or military or army or navy or “air force” or airforce or 
soldier* or “armed forces” or “armed service*” or “active duty*” or veteran* or 
paramedic or “first responder*” or (emergency n2 responder*) or ambulance or 
“emergency medical technician*” ) OR ( active n3 (individual* or population* 
or participant* or male* or female* or men or women or persons or students or 
adult* or patients or adolescent*) ) ) OR TI ( ( athletes or players or sport or 
sports or rugby or netball* or basketball* or hockey or volleyball or skiers or 
snowboard* or soccer or football* or lacrosse or rowers or gymnasts or “figure 
skaters” or dancers or tennis or badminton ) OR ( runners or (run* n2 
(marathon* or competitive* or casual* or recreation*)) or joggers or police* or 
officer* or firefighter* or firem* or “fire personnel” or military or army or navy 
or “air force” or airforce or soldier* or “armed forces” or “armed service*” or 
“active duty*” or veteran* or paramedic or “first responder*” or (emergency n2 
responder*) or ambulance or “emergency medical technician*” ) OR ( active n3 
(individual* or population* or participant* or male* or female* or men or 
women or persons or students or adult* or patients or adolescent*) ) ) OR SU 
( ( athletes or players or sport or sports or rugby or netball* or basketball* or 
hockey or volleyball or skiers or snowboard* or soccer or football* or lacrosse 
or rowers or gymnasts or “figure skaters” or dancers or tennis or badminton ) 
OR ( runners or (run* n2 (marathon* or competitive* or casual* or recreation*)) 
or joggers or police* or officer* or firefighter* or firem* or “fire personnel” or 
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military or army or navy or “air force” or airforce or soldier* or “armed forces” 
or “armed service*” or “active duty*” or veteran* or paramedic or “first 
responder*” or (emergency n2 responder*) or ambulance or “emergency medical 
technician*” ) OR ( active n3 (individual* or population* or participant* or 
male* or female* or men or women or persons or students or adult* or patients 
or adolescent*) ) )
S2 SU (injur* or pain* or tear or tears or sprain* or strain* or dislocation* or 
impingement* or instability )
S3 ( (injur* or pain* or tear or tears or sprain* or strain* or dislocation* or 
impingement* or instability) n6 (risk or risks or predict* or associat* or 
correlat* or screen* or prevent* or sport* or athletic or running) ) OR ( (injur* 
or pain* or tear or tears or sprain* or strain* or dislocation* or impingement* or 
instability) n8 (“lower extremit*” or “lower limb*” or hip or hips or thigh or 
thighs or leg or legs or knee or knees or ankle* or foot or foots or toe or toes or 
ACL or PCL or (cruciate n2 ligament*) or femoracetabular or femur or tibia* or 
patellofemoral or patella*) )
S4 S2 OR S3
S5 ( “lower extremit*” or “lower limb*” or hip or hips or thigh or thighs or leg or 
legs or knee or knees or ankle* or foot or foots or toe or toes or ACL or PCL or 
(cruciate n2 ligament*) or femoracetabular or femur or tibia* or patellofemoral 
or patella* ) OR ( run or running or jog* or squat* or minisquat* or balance or 
lunge or lunges or hop or jump or jumping or walk or walking or step-up or 
hurdle or gait )
S6 ( motor or movement or motion or dynamic or moving or exercise ) OR 
( (physical n1 (activit* or perform* or function*)) ) OR ( (function* n1 (activ* 
or perform*)) ) OR ( run or running or jog* or squat* or minisquat* or balance 
or lunge or lunges or hop or jump or jumping or walk or walking or step-up or 
hurdle or gait )
S7 ( “functional test*” or grade or grading or rating or rated or score or scoring or 
rank or ranked or ranking ) OR ( movement n2 (screen* or assess* or quality or 
performance or observation or observe* or test*) ) OR ( (performance or 
objective or observation* or quality or control) n5 (measur* or test* or 
instrument* or method or methods or index or indices or assess* or screen*) ) 
OR ( ( deficit* or varus or valgus or asymmetr* or “compensatory movement”) 
and (measur* or test* or instrument* or method or methods or index or indices 
or assess* or screen* ) )
S8 ( (Lunge or Squat or Hop or jump or Reach or Cutting or Step-up or Balance or 
Push-up or Lift or Rotation or walk*) n3 (test* or task* or assessment) ) OR 
( “gait analys*” or “gait evaluation*” or “deep squat*” or “one leg squat*” or 
mini-squat* or “mini squat*” or “in line lunge*” or “inline lunge*” or “double 
leg drop” or “hop and hold*” or “Hurdle step*” or “single leg pickup” or “single 
leg pick-up” or “single leg land” or “single leg balance” or “leg raise” or “tuck 
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jump” or “vertical jump” or “drop jump” or “functional movement screen*” or 
“landing error scoring system*” or “balance error scoring system*” or ppm-16 ) 
OR ( (nine-test or movement or performance or function) n3 “screening 
battery” )
S9 (S5 AND S6 AND S7) OR S8
S10 TI(predict* or associat* or correlat*)
S11 (“discriminant analys*” or “health status indicators” or “health indicators” or 
“predictive value” or “receiver operator curve*” or ROC or “likelihood ratio*” 
or specificity ) OR ( (predict* or correlat* or associat*) n10 (injur* or pain* or 
tear or tears or sprain* or strain* or dislocation* or impingement* or 
instability) ) OR ( (positive* or negative* or high* or low) n4 correlat*) ) OR 
( “outcome assessment” or “outcome measure*” or “observer variation*” or 
instrumentation or psychometr* or clinimetr* or clinometr* or reproducib* or 
reliab* or unreliab* or valid* or coefficient or homogeneity or homogeneous or 
“internal consistency”)
S12 (item n5 (correlation* or selection* or reduction*) ) OR ( “cronbach* alpha” or 
agreement or precision or imprecision or “precise value*” or test-retest or (test 
n3 retest) or stability ) OR ( interrater or inter-rater or intrarater or intra-rater or 
intertester or inter-tester or intratester or intra-tester or interobserver or inter-
observer or intraobserver or intraobserver or intertechnician or inter-technician 
or intratechnician or intra-technician or interexaminer or inter-examiner or 
intraexaminer or intra-examiner or interassay or inter-assay or intraassay or 
intra-assay or interindividual or inter-individual or intraindividual or intra-
individual or interparticipant or interparticipant or intraparticipant or intra-
participant )
S13 ( (replicab* or repeated) n6 (measure or measures or findings or result or results 
or test or tests) ) OR ( kappa* or repeatab* or generaliza* or generalisa* or 
concordance or (intraclass and correlation*) or discriminative or “known group” 
or “factor analysis” or “factor analyses” or dimension* or subscale* ) OR 
(multitrait n6 scaling n6 analys*) OR ( “item discriminant” or “interscale 
correlation*” or error or errors or “individual variability” or “standard error of 
measurement” or sensitiv* or responsive* ) OR ( variability n8 (analysis or 
values) ) OR ( uncertainty n6 (measurement or measuring) ) OR ( (minimal or 
minimally or clinical or clinically or mall*) n6 (important or significant or 
detectable or real) n6 (change or difference) ) OR ( “meaningful change” or 
“ceiling effect” or “floor effect” or “item response model” or IRT or Rasch or 
“Differential item functioning” or DIF or “computer adaptive testing” or “item 
bank” or “cross-cultural equivalence” )
S14 S10 OR S11 OR S12 OR S13
S15 S1 AND S4 AND S9 AND S14
S16 TI ( mice or mouse or rat or rats or animal model* or bovine or rodent* ) OR TI 
( arthroplast* or arthroscop* or TKA or THA or surgery or surgical or 
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paraplegi* or brain injur* or stroke or post-stroke or concussion or 
polyneuropath* or fibromyalgia or multiple sclerosis or arteriosclerosis or 
cancer or neoplasm* or malignanc* or degenerative or “return to sport” or 
claudication or epidural or platelet-rich plasma or cadaver or spinal cord or 
spinal chord or vibration or arterial disease or caffeine or pregnan* or breast or 
breasts or steroid* ) OR TI ( (after or undergoing) n5 reconstruction)
S17 PT review OR PT (conference proceeding)
S18 SO “case report*” or “case stud*”
S19 TI ((case NOT (case control or case cohort or case crossover)) n4 (series or 
study or report*))
S20 S15 NOT (S16 OR S17 OR S18 OR S19)
e. Scopus—( ( ( ( ( TITLE-ABS-KEY ( athlet* OR players OR sport OR sports OR rugby 
OR netball* OR basketball* OR hockey OR volleyball OR skiers OR snowboard* OR 
soccer OR football* OR lacrosse OR rowers OR gymnasts OR “figure skaters” OR dancers 
OR tennis ) OR TITLE-ABS-KEY ( runners OR marathoners OR joggers OR police* OR 
officer* OR firefighter* OR firem* OR “fire personnel” OR military OR army OR navy OR 
“air force” OR airforce OR soldier* OR “armed forces” OR “armed service*” OR “active 
duty*” OR veteran* OR paramedic* ) OR TITLE-ABS-KEY ( “first responder*” OR 
ambulance OR “emergency medical technician*” ) OR TITLE-ABS-KEY ( ( active W/3 
( individual* OR population* OR participant* OR male* OR female* OR men OR women 
OR persons OR students OR adult* OR patients OR adolescent* ) ) ) ) ) AND ( ( TITLE-
ABS-KEY ( ( ( injur* OR pain* OR tear OR tears OR sprain* OR strain* OR dislocation* 
OR impingement* OR instability ) W/6 ( risk OR risks OR predict* OR associat* OR 
correlat* OR screen* OR prevent* OR sport* OR athletic OR running ) ) ) OR TITLE-ABS-
KEY ( ( ( injur* OR pain* OR tear OR tears OR sprain* OR strain* OR dislocation* OR 
impingement* OR instability ) W/8 ( “lower extremit*” OR “lower limb*” OR hip OR hips 
OR thigh OR thighs OR leg OR legs OR knee OR knees OR ankle* OR foot OR foots OR 
toe OR toes ) ) ) OR TITLE-ABS-KEY ( ( ( injur* OR pain* OR tear OR tears OR sprain* 
OR strain* OR dislocation* OR impingement* OR instability ) W/8 ( acl OR pcl OR 
“cruciate ligament*” OR femoracetabular OR femur OR tibia* OR patellofemoral OR 
patella ) ) ) ) ) AND ( ( ( ( TITLE-ABS-KEY ( “lower extremit*” OR “lower limb*” OR hip 
OR hips OR thigh OR thighs OR leg OR legs OR knee OR knees OR ankle* OR foot OR 
foots OR toe OR toes OR acl OR pcl OR “cruciate ligament*” OR femoracetabular OR 
femur OR tibia* OR patell* ) OR TITLE-ABS-KEY ( run OR running OR jog* OR squat* 
OR lunge OR lunges OR hop OR jump OR jumping OR walk OR walking OR step-up OR 
hurdle OR gait ) ) ) AND ( ( TITLE-ABS-KEY ( motor OR movement OR motion OR 
dynamic OR moving OR exercise ) OR TITLE-ABS-KEY ( ( physical W/1 ( activit* OR 
perform* OR function* ) ) ) OR TITLE-ABS-KEY ( ( function* W/1 ( activ* OR 
perform* ) ) ) OR TITLE-ABS-KEY ( run OR running OR jog* OR squat* OR minisquat* 
OR balance OR lunge OR lunges OR hop OR jump OR jumping OR walk OR walking OR 
step-up OR hurdle OR gait ) ) ) AND ( ( TITLE-ABS-KEY ( “functional test*” OR grade 
OR grading OR rating OR rated OR score OR scoring OR RANK OR ranked OR ranking ) 
Whittaker et al. Page 27
Br J Sports Med. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
OR TITLE-ABS-KEY ( movement W/2 ( screen* OR assess* OR quality OR performance 
OR observation OR observe* OR test* ) ) OR TITLE-ABS-KEY ( ( performance OR 
objective OR observation* OR quality OR control ) W/5 ( measur* OR test* OR 
instrument* OR method OR methods OR INDEX OR indices OR assess* OR screen* ) ) 
OR TITLE-ABS-KEY ( ( deficit* OR varus OR valgus OR asymmetr* OR “compensatory 
movement” ) AND ( measur* OR test* OR instrument* OR method OR methods OR 
INDEX OR indices OR assess* OR screen* ) ) ) ) ) OR ( ( TITLE-ABS-KEY ( ( lunge OR 
squat OR hop OR jump OR reach OR cutting OR step-up OR balance OR push-up OR lift 
OR rotation OR walk* ) W/3 ( test* OR task* OR assessment ) ) OR TITLE-ABS-KEY 
( “gait analys*” OR “gait evaluation*” OR “deep squat*” OR “one leg squat*” OR mini-
squat* OR “mini squat*” OR “in line lunge*” OR “inline lunge*” OR “double leg drop” OR 
“hop and hold*” OR “Hurdle step*” ) OR TITLE-ABS-KEY ( “single leg pickup” OR 
“single leg pick-up” OR “single leg land” OR “single leg balance” OR “leg raise” OR “tuck 
jump” OR “vertical jump” OR “drop jump” OR “functional movement screen*” OR 
“landing error scoring system*” ) OR TITLE-ABS-KEY ( “balance error scoring system*” 
OR ppm-16 ) OR ( ( nine-test OR movement OR performance OR function ) n3 “screening 
battery” ) ) ) ) ) AND ( ( ( TITLE ( predict* OR associat* OR correlat* ) OR TITLE-ABS-
KEY ( “discriminant analys*” OR “health status indicators” OR “health indicators” OR 
“predictive value” OR “receiver operator curve*” OR roc OR “likelihood ratio*” OR 
specificity ) OR TITLE-ABS-KEY ( ( predict* OR correlat* OR associat* ) W/10 ( injur* 
OR pain* OR tear OR tears OR sprain* OR strain* OR dislocation* OR impingement* OR 
instability ) ) OR TITLE-ABS-KEY ( ( positive* OR negative* OR high* OR low ) W/4 
correlat* ) OR TITLE-ABS-KEY ( “observer variation*” OR instrumentation OR 
psychometr* OR clinimetr* OR clinometr* OR reproducib* OR reliab* OR unreliab* OR 
valid* OR coefficient OR homogeneity OR homogeneous OR “internal consistency” ) ) ) 
OR ( ( TITLE-ABS-KEY ( item W/5 ( correlation* OR selection* OR reduction* ) ) OR 
TITLE-ABS-KEY ( “cronbach* alpha” OR agreement OR precision OR imprecision OR 
“precise value*” OR test-retest OR ( test W/3 retest ) ) OR TITLE-ABS-KEY ( interrater 
OR inter-rater OR intrarater OR intra-rater OR intertester OR inter-tester OR intratester OR 
intra-tester OR interobserver OR inter-observer OR intraobserver OR intraobserver OR 
intertechnician OR intertechnician OR intratechnician ) OR TITLE-ABS-KEY ( intra-
technician OR interexaminer OR inter-examiner OR intraexaminer OR intra-examiner OR 
interassay OR inter-assay OR intraassay OR intra-assay OR interindividual OR inter-
individual OR intraindividual ) OR TITLE-ABS-KEY ( intra-individual OR interparticipant 
OR inter-participant OR intraparticipant OR intra-participant ) ) ) OR ( ( TITLE-ABS-KEY 
( ( replicab* OR repeated ) W/6 ( measure OR measures OR findings OR result OR results 
OR test OR tests ) ) OR TITLE-ABS-KEY ( kappa* OR repeatab* OR generaliza* OR 
generalisa* OR concordance OR ( intraclass AND correlation* ) ) OR TITLE-ABS-KEY 
( discriminative OR “known group” OR “factor analysis” OR “factor analyses” OR 
dimension* OR subscale* ) OR TITLE-ABS-KEY ( multitrait W/6 scaling W/6 analys* ) 
OR TITLE-ABS-KEY ( “item discriminant” OR “interscale correlation*” OR “individual 
variability” OR “standard error of measurement” OR sensitiv* OR responsive* ) OR TITLE-
ABS-KEY ( ( minimal OR minimally OR clinical OR clinically OR mall* ) W/6 ( important 
OR significant OR detectable OR real ) W/6 ( change OR difference ) ) OR TITLE-ABS-
KEY ( “meaningful change” OR “ceiling effect” OR “floor effect” OR “item response 
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model” OR irt OR rasch OR “Differential item functioning” OR dif OR “computer adaptive 
testing” OR “item bank” OR “cross-cultural equivalence” ) ) ) ) ) AND NOT ( ( TITLE 
( mice OR mouse OR rat OR rats OR animal model* OR bovine OR rodent* ) OR TITLE 
( arthroplast* OR arthroscop* OR tka OR tha OR surgery OR surgical OR paraplegi* OR 
brain injur* OR stroke OR post-stroke OR concussion OR polyneuropath* OR fibromyalgia 
OR “multiple sclerosis” ) OR TITLE ( arteriosclerosis OR cancer OR neoplasm* OR 
malignanc* OR degenerative OR “return to sport” OR claudication OR epidural OR platelet-
rich plasma OR cadaver OR spinal cord OR spinal chord OR vibration OR arterial disease 
OR caffeine OR pregnan* OR breast ) OR TITLE ( ( after OR undergoing ) n5 
reconstruction ) ) ) ) AND NOT ( ( TITLE ( “case report” OR “case study” OR “case 
series” ) AND KEY ( “case report” OR “case study” OR “case series” ) AND SRCTITLE 
( “case report*” OR “case stud*” ) ) ) AND ( LIMIT-TO ( LANGUAGE, “English” ) ) AND 
( EXCLUDE ( DOCTYPE, “re” ) OR EXCLUDE ( DOCTYPE, “cp” ) OR EXCLUDE 
( DOCTYPE, “cr” ) )
RESULTS
Database Date searched # of results
Medline Jan 5, 2016 1716
CINAHL Jan 5, 2016 1329
EMBASE Jan 5, 2016 1505
SportDiscus Jan 5, 2016 1497
Scopus Jan 5, 2016 2172
Total 8219
APPENDIX 2: DOWN’S AND BLACK QUALITY ASSESSMENT CRITERIA 
SCORED FOR INCLUDED STUDIES
Item Score
1 Is the hypothesis/aim/objective of the study clearly described? yes=1; no=0
2 Are the main outcomes to be measured clearly described in the Introduction or Methods section? yes=1; no=0
3 Are the characteristics of the patients included in the study clearly described? yes=1; no=0
4 * Are the interventions of interest clearly described? yes=1; no=0
5 Are the distributions of principal confounders in each group of subjects to be 
compared clearly described? yes=2; partially=1; no=0
6 Are the main findings of the study clearly described? yes=1; no=0
7 Does the study provide estimates of the random variability in the data for the 
main outcomes? yes=1; no=0
8
*
 Have all important adverse events that may be a consequence of the 
intervention been reported? yes=1; no=0
9 Have the characteristics of patients lost to follow-up been described? yes=1; no=0
10 Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001? yes=1; no=0
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Item Score
11 Were the subjects asked to participate in the study representative of the entire population from which they were recruited? yes=1; no=0
12 Were those subjects who were prepared to participate representative of the 
entire population from which they were recruited? yes=1; no=0
13 Were the staff, places, and facilities where the patients were treated, 
representative of the treatment the majority of patients receive? yes=1; no=0
14
*
 Was an attempt made to blind study subjects to the intervention they have 
received? yes=1; no=0
15 Was an attempt made to blind those measuring the main outcomes of the intervention? yes=1; no=0
16 If any of the results of the study were based on “data dredging”, was this made 
clear? yes=1; no=0
17
In trials and cohort studies, do the analyses adjust for different lengths of 
follow-up of patients, or in case-control studies, is the time period between the 
intervention and outcome the same for cases and controls?
yes=1; no=0
18 Were the statistical tests used to assess the main outcomes appropriate? yes=1; no=0
19 * Was compliance with the intervention/s reliable? yes=1; no=0
20 Were the main outcome measures used accurate (valid and reliable)? yes=1; no=0
21
Were the patients in different intervention groups (trials and cohort studies) or 
were the cases and controls (case-control studies) recruited from the same 
population?
yes=1; no=0
22
Were study subjects in different intervention groups (trials and cohort studies) 
or were the cases and controls (case-control studies) recruited over the same 
period of time?
yes=1; no=0
23 * Were study subjects randomized to intervention groups? yes=1; no=0
24
*
 Was the randomized intervention assignment concealed from both patients 
and health care staff until recruitment was complete and irrevocable? yes=1; no=0
25 Was there adequate adjustment for confounding in the analyses from which the 
main findings were drawn? yes=1; no=0
26 Were losses of patients to follow-up taken into account? yes=1; no=0
27
*
 Did the study have sufficient power to detect a clinically important effect 
where the probability value for a difference being due to chance is less than 
5%?
Size of smallest intervention 
group: <n1=0; n1-n2=1; n3-
n4=2; n5-n6=3; n7-n8=4; 
n8+=5
Items 1–10 = reporting, 11–13 = external validity, 14–20 = internal validity (bias), 21–26 = internal validity (confounding) 
and 27 = power.
*
not applicable to observational studies.
APPENDIX 3: LEVELS OF EVIDENCE ADAPTED FROM THE OXFORD 
CENTRE FOR EVIDENCE-BASED MEDICINE MODEL 200916
Level Description
1
a Systematic reviews (with homogeneity) of randomized controlled trials
b Individual randomized controlled trials (with narrow confidence intervals)
c All or none randomized controlled trials
2
a Systematic reviews (with homogeneity) of cohort studies
b Individual cohort study or low quality randomized controlled trials (e.g. <80% follow-up)
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Level Description
c “Outcomes” research; ecological studies
3
a Systematic review (with homogeneity) of case-control studies
b Individual case-control study
c Cross-sectional studies
4 Case-series (and poor quality cohort and case-control studies)
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles”
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WHAT ARE THE NEW FINDINGS
• There is conflicting level 4 evidence that movement quality outcomes are risk 
factors for lower extremity injury in sport and military/first-responder 
occupation populations.
• There is a need for consistency in injury definition amongst studies 
attempting to determine the relationship between a movement quality 
outcome and subsequent injury.
• Based on the work done in the field it is recommended that investigators focus 
on high quality cohort studies to identify the most relevant movement quality 
outcomes for predicting injury risk that account for the multifactorial nature 
of injury by ensuring adequate sample size and employing relevant 
biostatistical techniques.
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Figure 1. 
Study identification PRISMA flowsheet
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